Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narsoplimab - Omeros Corporation

Next Previous
X
Search
Drug Profile

Narsoplimab - Omeros Corporation

Alternative Names: anti-MASP-2 monoclonal antibody; MASP-2 antibody - Omeros Corporation; MASP-2 therapeutic; OMS 00620646; OMS 620646; OMS 721

Latest Information Update: 13 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Omeros Corporation
  • Developer Omeros Corporation; Quantum Leap Healthcare Collaborative
  • Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Monoclonal antibodies; Urologics; Vascular disorder therapies
  • Mechanism of Action Immunomodulators; MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic microangiopathies; IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Thrombotic microangiopathies
  • Phase III Haemolytic uraemic syndrome; IgA nephropathy; Immediate hypersensitivity
  • Phase II Glomerulonephritis; Lupus nephritis; Membranous glomerulonephritis; SARS-CoV-2 acute respiratory disease
  • No development reported Stroke; Wet age-related macular degeneration

Most Recent Events

  • 07 Aug 2024 Omeros Corporation plans to launch narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
  • 09 Nov 2023 Omeros Corporation expects a decision from the US FDA regarding the approval of narsoplimab for Thrombotic microangiopathies, in mid 2024
  • 16 Oct 2023 Omeros Corporation discontinues a phase III ARTEMIS-IGAN trial in IgA nephropathy in Sweden, Czech Republic, Spain, Slovakia, Poland, Lithuania, Hungary, Bulgaria, Belgium, Austria and Australia (IV), due to absence of statistical significance (NCT03608033)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top